T. Rowe Price Associates
LFCR icon

T. Rowe Price Associates’s Lifecore Biomedical LFCR Stock Holding History

T. Rowe Price Associates’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$119K Buy
22,560
+4,880
+28% +$24.6K ﹤0.01% 3121
2026
Q1 		$66K Buy
17,680
+1,034
+6% +$7.14K ﹤0.01% 3048
2025
Q4 		$137K Buy
16,646
+2,826
+20% +$20.9K ﹤0.01% 2902
2025
Q3 		$102K Buy
13,820
+700
+5% +$5.3K ﹤0.01% 2920
2025
Q2 		$107K Buy
13,120
+2,321
+21% +$15.6K ﹤0.01% 2879
2025
Q1 		$77K Buy
+10,799
New +$67.1K ﹤0.01% 2873

Other funds holding LFCR

WC
Wynnefield Capital New York $145M AUM 14.57% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $40.6M AUM 156.55% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $154M AUM 15.9% 1-Year Est. Return
3C
325 Capital New York $419M AUM 75.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
QOP
Quinn Opportunity Partners Charlottesville, Virginia $2.16B AUM 28.56% 1-Year Est. Return

T. Rowe Price Associates's LFCR Position: Q2 2026 in Review

T. Rowe Price Associates increased its Lifecore Biomedical (LFCR) stake by 28% in Q2 2026, buying an estimated $24.6K and bringing the position to 22,560 shares worth $119K. The position accounts for ﹤0.01% of the portfolio, ranked #3121.

T. Rowe Price Associates first reported a position in LFCR in Q1 2025 and has held it in 6 quarters since. The position peaked at $137K in Q4 2025. 98 funds tracked by Wall St. Rank hold LFCR as of Q2 2026.

  • T. Rowe Price Associates held 22,560 shares of Lifecore Biomedical worth $119K as of Q2 2026.
  • T. Rowe Price Associates bought 4,880 Lifecore Biomedical shares in Q2 2026, an estimated $24.6K.
  • Lifecore Biomedical made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #3121 holding.
  • T. Rowe Price Associates first reported a position in Lifecore Biomedical in Q1 2025 and has held it in 6 quarters since.
  • T. Rowe Price Associates's Lifecore Biomedical position peaked at $137K in Q4 2025.
  • 98 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.